| 内皮素受体拮抗剂用于肺动脉高压的治疗进展 |
| |
| 引用本文： | 安培,;白蕾,;孟舒,;荆志成. 内皮素受体拮抗剂用于肺动脉高压的治疗进展[J]. 世界临床药物, 2014, 0(6): 326-331 |
| |
| 作者姓名： | 安培, 白蕾, 孟舒, 荆志成 |
| |
| 作者单位： | [1]上海交通大学医学院附属新华医院心内科,上海200092; [2]东南大学附属中大医院老年科,南京210009; [3]同济大学附属上海市肺科医院心肺循环中心,上海200433; [4]中国医学科学院,北京协和医学院,国家心血管病中心,阜外心血管病医院,心血管疾病国家重点实验室,北京100037 |
| |
| 摘 要： | 肺动脉高压（PAH）是一类以肺血管阻力进行性升高为主要特征的心肺血管疾病,最终可导致右心衰竭甚至死亡。早期发现PAH患者中内皮素明显高于正常,可引起肺血管的持续收缩及重构。内皮素受体拮抗剂可阻断该通路进而起到降低肺高压的作用。但目前国内临床上对于该类药物了解甚少。本文参考国内外文献对内皮素受体拮抗剂在PAH中的作用机制及临床应用作简要综述,旨在指导临床用药,使更多患者获益。
|
| 关 键 词： | 内皮素 内皮素受体拮抗剂 肺动脉高压(PAH) |
Progress of endothelin receptor antagonists for the treatment of pulmonary arterial hypertension |
| |
| Affiliation: | AN Pei, BAI Lei, MENG Shu, JING Zhi-cheng (1.Department of Cardiology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092; 2. Department of Geriatrics, Zhongda Hospital Southeast University, Nanjing 210009; 3. Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tong]i university, School of Medicine, Shanghai 200433 4. State Key Laboratory of Cardiovascular Diseases Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China) |
| |
| Abstract: | PPulmonary arterial hypertension（PAH） is a pulmonary vascular disease by stepping up pulmonary vascular resistance and finally leads to right heart failure. Earlier studies showed that the endothelin-1 levels of pulmonary vascular in PAH patient is significantly higher than normal, which can cause sustained contraction and restructure. Endothelin receptor antagonist can be used to treat PAH. This review summarizes the mechanism and clinical application of endothelin receptor antagonists on PAH therapy. |
| |
| Keywords: | endothelin endothelin receptor antagonist pulmonary arterial hypertension（PAH） |
| 本文献已被 维普 等数据库收录！ |
|
